Mar. 19 at 2:45 PM
$CHRS was reviewing the tagmokitug abstract and hadn't noticed before that the disease control rate is mentioned in the bottom left corner for the phase 1 monotherapy. It states "Stable disease observed in NSCLC,OC, PDAC, EC (~ 1 yr), and CRC" & "Disease control rate: 47%"
While the primary focus is typically on objective response rates & complete responses, one overlooked measurement is disease control rate. This is a measure of how many patients didn't see there tumors grow on treatment (so they didn't necessarily see their tumors shrink but they also didn't continue to grow). Tagmo achieved a 47% disease control rate which is huge in my opinion. Compare that to the DCR of PD-1s as mono therapy or chemo which average 30% at best, tagmo is already showing quite a bit of efficacy.
https://www.coherus.com/wp-content/uploads/2025/10/SITC_2025_CHS114_Coherus_Abstract_640.pdf
